Thompson Investment Management Inc. Sells 625 Shares of Jazz Pharmaceuticals PLC (JAZZ)

Thompson Investment Management Inc. lessened its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 11.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,075 shares of the specialty pharmaceutical company’s stock after selling 625 shares during the quarter. Thompson Investment Management Inc.’s holdings in Jazz Pharmaceuticals were worth $853,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Stratos Wealth Partners LTD. purchased a new stake in Jazz Pharmaceuticals in the third quarter worth about $106,000. Tiverton Asset Management LLC purchased a new stake in Jazz Pharmaceuticals in the second quarter worth about $198,000. Moloney Securities Asset Management LLC purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at approximately $204,000. FDx Advisors Inc. purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at approximately $244,000. Finally, Cadence Capital Management LLC purchased a new stake in shares of Jazz Pharmaceuticals during the third quarter valued at approximately $263,000. Institutional investors and hedge funds own 92.95% of the company’s stock.

A number of equities research analysts have recently commented on JAZZ shares. Zacks Investment Research cut shares of Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, July 16th. BidaskClub cut shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 17th. Piper Jaffray Companies reiterated a “buy” rating and set a $213.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, August 8th. Cantor Fitzgerald set a $203.00 price target on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 7th. Finally, Stifel Nicolaus increased their price target on shares of Jazz Pharmaceuticals from $180.00 to $205.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and fourteen have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $191.94.

In related news, CEO Bruce C. Cozadd sold 1,300 shares of the stock in a transaction that occurred on Friday, September 21st. The shares were sold at an average price of $164.36, for a total transaction of $213,668.00. Following the transaction, the chief executive officer now owns 281,215 shares in the company, valued at $46,220,497.40. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction that occurred on Tuesday, August 14th. The shares were sold at an average price of $175.70, for a total transaction of $35,140.00. Following the transaction, the executive vice president now owns 25,572 shares in the company, valued at approximately $4,493,000.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 16,730 shares of company stock worth $2,796,532. 3.90% of the stock is owned by insiders.

Shares of Jazz Pharmaceuticals stock opened at $145.72 on Monday. The company has a market cap of $8.78 billion, a P/E ratio of 15.24, a P/E/G ratio of 0.80 and a beta of 1.06. Jazz Pharmaceuticals PLC has a twelve month low of $130.15 and a twelve month high of $184.00. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.62 and a current ratio of 4.29.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.32 by $0.26. The company had revenue of $469.37 million for the quarter, compared to the consensus estimate of $482.64 million. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The firm’s revenue for the quarter was up 14.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.22 earnings per share. On average, research analysts anticipate that Jazz Pharmaceuticals PLC will post 11.66 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Thompson Investment Management Inc. Sells 625 Shares of Jazz Pharmaceuticals PLC (JAZZ)” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/11/12/thompson-investment-management-inc-sells-625-shares-of-jazz-pharmaceuticals-plc-jazz.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: Fundamental Analysis and Individual Investors

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply